secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001558370-24-007059
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix Q1 revenue $32.1M (+12.7%); net loss $10.1M; FDA breakthrough for P-tau217 test
--------------------------------------------------------------------------------

- Revenue $32.1M (+12.7% YoY); net loss $10.1M (increase of $4.0M YoY).
- GAAP gross margin 61.2% (up 170 bps); non-GAAP gross margin 54.5% (up 140 bps).
- FY 2024 guidance unchanged: revenue $139-$144M, GAAP gross margin 57-61%, non-GAAP 51-55%.
- Director Brian J. Blaser resigned board eff. May 3, 2024 to become CEO of QuidelOrtho; no disagreement.
- Simoa P-tau217 blood test granted FDA Breakthrough Device; Lilly launched CertuitAD test on SP-X platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/0001558370-24-007059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/tmb-20240502x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer